Myrexis (Myrexis) Debt-to-Asset

: 0.00 (As of Jun. 2013)

View and export this data going back to 2013. Start your Free Trial

Myrexis's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2013 was $0.00 Mil. Myrexis's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2013 was $0.00 Mil. Myrexis's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2013 was $1.24 Mil. Myrexis's debt to asset for the quarter that ended in Jun. 2013 was 0.00.

Myrexis Debt-to-Asset Historical Data

The historical data trend for Myrexis's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Myrexis Annual Data

Trend

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Debt-to-Asset

Myrexis Quarterly Data
	Sep08	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13
Debt-to-Asset																-	-	-	-	-

Competitive Comparison

For the Shell Companies subindustry, Myrexis's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myrexis Debt-to-Asset Distribution

For the Diversified Financial Services industry and Financial Services sector, Myrexis's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Myrexis's Debt-to-Asset falls into.

Myrexis Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Myrexis's Debt-to-Asset for the fiscal year that ended in Jun. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	1.237
	=	0.00

Myrexis's Debt-to-Asset for the quarter that ended in Jun. 2013 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	1.237
	=	0.00

Myrexis (OTCPK:MYRX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Myrexis Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Myrexis's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Myrexis (Myrexis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Myrexis Inc (OTCPK:MYRX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

630 Fifth Avenue, Suite 2260, New York, NY, USA, 10020

Website

http://www.myrexis.com

Myrexis Inc is engaged in evaluating strategic alternatives, such as identifying, evaluating and making financial investments in life sciences assets.

Executives

Xstelos Corp.	10 percent owner	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Steven D Scheiwe	director	1741 EDGEFIELD LANE, ENCINITAS CA 92024
Pearce Michael Cooper	director	213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Jonathan Couchman	director, officer: Chairman, President and CEO	630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
First Eagle Investment Management, Llc	10 percent owner	1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Gerald P. Belle	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
David W Gryska	director, officer: Chief Operating Officer	749 N MARY AVE, SUNNYVALE CA 94085
Richard B Brewer	director, officer: President and CEO	C/O DENDREON CORP, 3005 1ST AVE, SEATTLE WA 98121
Timothy R Franson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Robert Forrester	director	C/O COMBINATORX, INCORPORATED, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Adrian N Hobden	director, officer: President and CEO	320 WAKARA WAY, SALT LAKE CITY UT 84108
W Wayne Laslie	officer: Chief Operating Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108

Myrexis (Myrexis) Headlines

From GuruFocus

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-17-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-K)

By gurufocus 10qk • 09-13-2010

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 11-12-2009

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-09-2011

Myriad Pharmaceuticals Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 02-16-2010